

Accepted Manuscript

Title: Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing

Author: Xuefei Zhang Yanlin Li Changhong Liu Weifeng Wang Mo Li Desheng Lv Ge Sun Hui Chen Xiaowei Dong Zhibo Miao Ming Yao Kai Wang Hui Tian



PII: S0169-5002(17)30492-0
DOI: <http://dx.doi.org/doi:10.1016/j.lungcan.2017.08.019>
Reference: LUNG 5456

To appear in: *Lung Cancer*

Received date: 11-5-2017
Revised date: 7-8-2017
Accepted date: 21-8-2017

Please cite this article as: Zhang X, Li Y, Liu C, Wang W, Li M, Lv D, Sun G, Chen H, Dong X, Miao Z, Yao M, Wang K, Tian H, Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing, *Lung Cancer* (2017), <http://dx.doi.org/10.1016/j.lungcan.2017.08.019>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Identification of a Novel *KIF13A-RET* Fusion in Lung Adenocarcinoma by Next-generation Sequencing

Xuefei Zhang^{1,2}, Yanlin Li³, Changhong Liu², Weifeng Wang³, Mo Li², Desheng Lv², Ge Sun², Hui Chen³, Xiaowei Dong³, Zhibo Miao³, Ming Yao³, Kai Wang^{3,4}, Hui Tian^{1,*}

¹Department of Thoracic Surgery, Qilu Hospital of Shandong University Ji'nan City, Shandong province, China, 250012

²Department of Thoracic Surgery, The Second Hospital of Dalian Medical University, Dalian City, Liaoning Province, China, 116023

³Origimed, Shanghai, China

⁴Center for Precision Medicine, Zhejiang University International Hospital, Hangzhou, Zhejiang, China

*Corresponding Author:

Conflict of interest

YL, WW, HC, XD, MY, KW are employees of Origimed.

Highlights

- RET fusions have been reported in 1-2% of lung adenocarcinomas.
- RET fusion are associated with clinical benefit from multi-kinase inhibitors.
- We describe a novel RET-fusion in lung adenocarcinomas by NGS.
- NGS provide more comprehensive breakpoint information on partner genes
- The new RET fusions have immediate clinical implications.

Download English Version:

<https://daneshyari.com/en/article/8453986>

Download Persian Version:

<https://daneshyari.com/article/8453986>

[Daneshyari.com](https://daneshyari.com)